Posted by Michael Wonder on 14 May 2020
Camurus' Buvidal reimbursed in Sweden for the treatment of opioid dependence
14 May 2020 - Buvidal (buprenorphine) prolonged release injection receives reimbursement in Sweden from the 15 May 2020 after approval by TLV.
Following a decision by the Dental and Pharmaceutical Benefits Agency, TLV, Buvidal (buprenorphine) prolonged release injection has received reimbursement in Sweden for treatment of opioid dependence.
Buvidal is approved for use in adults and adolescents over 16 years who are also receiving medical, social and psychological support.
